Kyverna Therapeutics, Inc. (KYTX) Financials

$2.78

south_east
-$0.06 (-2.11%)
Day's range
$2.71
Day's range
$2.89
$20M$20M$0$0-$20M-$20M-$40M-$40M-$60M-$60M-$80M-$80MEarning202120212022202220232023-380%-380%-400%-400%-420%-420%-440%-440%-460%-460%-480%-480%Profit Margin
Profit Margin
Revenue
Earnings

KYTX Income statement / Annual

Last year (2023), Kyverna Therapeutics, Inc.'s total revenue was $0.00, a decrease of 100.00% from the previous year. In 2023, Kyverna Therapeutics, Inc.'s net income was -$60.37 M. See Kyverna Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021
Period Ended 12/31/2023 12/31/2022 12/31/2021
Operating Revenue $0.00 $7.03 M $5.66 M
Cost of Revenue $1.71 M $1.05 M $586,000.00
Gross Profit -$1.71 M $5.97 M $5.07 M
Gross Profit Ratio 0 0.85 0.9
Research and Development Expenses $49.92 M $28.40 M $25.85 M
General & Administrative Expenses $12.48 M $8.01 M $6.15 M
Selling & Marketing Expenses $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $12.48 M $8.01 M $6.15 M
Other Expenses -$55,000.00 -$9,000.00 -$2,000.00
Operating Expenses $62.41 M $36.41 M $32.00 M
Cost And Expenses $62.41 M $36.41 M $32.00 M
Interest Income $2.28 M $565,000.00 $1,000.00
Interest Expense $187,000.00 $65,000.00 $3,000.00
Depreciation & Amortization $1.71 M $1.05 M $586,000.00
EBITDA -$58.47 M -$27.78 M -$25.76 M
EBITDA Ratio 0 -3.95 -4.55
Operating Income Ratio 0 -4.18 -4.66
Total Other Income/Expenses Net $2.04 M $491,000.00 -$4,000.00
Income Before Tax -$60.37 M -$28.89 M -$26.35 M
Income Before Tax Ratio 0 -4.11 -4.66
Income Tax Expense $0.00 $56,000.00 $1,000.00
Net Income -$60.37 M -$28.89 M -$26.35 M
Net Income Ratio 0 -4.11 -4.66
EPS -0.0001 -1.12 -1.02
EPS Diluted -0.0001 -1.12 -1.02
Weighted Average Shares Out $673.62 M $25.80 M $25.80 M
Weighted Average Shares Out Diluted $673.62 M $25.80 M $25.80 M
Link